{"id":378281,"date":"2023-12-11T04:30:31","date_gmt":"2023-12-11T09:30:31","guid":{"rendered":"https:\/\/platohealth.ai\/inside-vertexs-decades-long-quest-to-develop-a-new-class-of-non-opioid-painkillers\/"},"modified":"2023-12-11T07:30:21","modified_gmt":"2023-12-11T12:30:21","slug":"inside-vertexs-decades-long-quest-to-develop-a-new-class-of-non-opioid-painkillers","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/inside-vertexs-decades-long-quest-to-develop-a-new-class-of-non-opioid-painkillers\/","title":{"rendered":"Inside Vertex\u2019s decades-long quest to develop a new class of non-opioid painkillers","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

S<\/span><\/span>AN DIEGO \u2014 For decades, the biotech industry has tried \u2014 and repeatedly failed \u2014 to develop new and effective painkillers without the addictive potential of opioids. But there\u2019s reason to think that could begin to change soon.<\/p>\n

Vertex Pharmaceuticals is on the cusp of announcing results from late-stage trials of a drug that precisely blocks pain-sensing neurons from signaling the brain. The company will announce data early next year from Phase 3 studies testing the molecule\u2019s effectiveness at treating post-surgical pain. And before the end of the month, Vertex will share results from a mid-stage trial in people with diabetes who have chronic nerve pain.<\/p>\n

\n

advertisement<\/p>\n<\/div>\n

There\u2019s much riding on the outcome of these studies, both for patients and for Vertex. Pain is one of the most common and debilitating symptoms and is the leading cause<\/a> of disability globally.<\/p>\n

\n
\n
\n

\n\t\t\t\t\t\tGet unlimited access to award-winning journalism and exclusive events.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n<\/p><\/div>\n<\/p><\/div>\n